NASDAQ NMS - GLOBAL MARKET · CVKD
+0.00% · +$0.0000 · Vol Not reported
Market closed · last close shown
Cadrenal Therapeutics Inc

Cadrenal Therapeutics Inc

Pharmaceuticals
$1.61
Card
Relationship Map

Veridion Score

BETALOW CONF · 4/6 factorsMethodology
Earnings absence reason unknown · Sentiment absence reason unknown
CVKD
Cadrenal Therapeutics Inc
Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
NEUTRAL

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

54/ 100
Veridion Score
NEUTRAL · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 4/6 factors with data · Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is CVKD moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading CVKD catalysts
About Cadrenal Therapeutics Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2023
Employees
5
Country
US

Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$1.61
Last session
Day high
$1.61
Last session
Day low
$1.61
Last session
Previous close
$1.61
52W high
$14.20
-88.66% from high
52W low
$1.59
0% of range
Market cap
$5.7M
EPS
$-5.3600
Beta
1.29
Shares out
3.6M
Avg volume
56.2K
VWAP
$1.61
Last session
Price history computed in-house
1W
-8.52%
1M
-21.08%
3M
-68.98%
1Y
-87.10%
YTD
-76.25%
SMA 50 $2.49 · below
SMA 200 $6.01 · below
52W position 0%

CVKD overview

Veridion Score
54
Registered · 2026-08-21
4 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around CVKD.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading CVKD Form 4 filings
Public disclosures

Congress activity in CVKD

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for CVKD in the cached public ledger.

Federal contracts

CVKD contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for CVKD in this window.
Lobbying spend

CVKD lobbying filings, year to date.

Registered lobbying filings matched to Cadrenal Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for CVKD in this window.
Loading news for CVKD
Analyst ratings
Sovereign unlock shows live analyst consensus for CVKD.
Options
Sovereign unlock shows live options positioning for CVKD.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.